Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT02953509 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

178

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated early due to the magrolimab program discontinuation.

Conditions

Non Hodgkin Lymphoma

Interventions

DRUG: Magrolimab
DRUG: Rituximab
DRUG: Gemcitabine
DRUG: Oxaliplatin
DRUG: Allopurinol

Sponsor

Gilead Sciences

Collaborators

[object Object]